Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10307413 | 0.87 | ALDH1A1 (0.57) | ALDH1A1RECQLGLAHTTTSHR | |
| SCHEMBL10307398 | 0.85 | GLA (0.69) | ALDH1A1RECQLGLAHTTTSHR | |
| SCHEMBL10307399 | 0.84 | ALDH1A1 (0.56) | ALDH1A1RECQLGLAHTTTSHR | |
| SCHEMBL3841660 | 0.83 | ALDH1A1 (0.57) | ALDH1A1RECQLGLAHTTTSHR | |
| Bromide SCHEMBL11418551 | 0.83 | GLA (0.72) | ALDH1A1RECQLGLAHTTTSHR | |
| SCHEMBL12205239 | 0.83 | ALDH1A1 (0.64) | ALDH1A1RECQLGLAHTTTSHR | |
| SCHEMBL10307400 | 0.82 | ALDH1A1 (0.56) | ALDH1A1RECQLGLAHTTTSHR | |
| Bromide SCHEMBL4504186 | 0.82 | ALDH1A1 (0.56) | ALDH1A1RECQLGLAHTTTSHR | |
| SCHEMBL8038922 | 0.82 | ALDH1A1 (0.56) | ALDH1A1RECQLGLAHTTTSHR | |
| SCHEMBL5323844 | 0.81 | ALDH1A1 (0.51) | ALDH1A1RECQLGLAHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106661735-B | Palladium plating solution and palladium coating film obtained using the same | 日本高纯度化学株式会社 | 2019-12-10 | — | — | CN | claimed |
| CN-106661735-B | Palladium plating solution and palladium coating film obtained using the same | 日本高纯度化学株式会社 | 2019-12-10 | — | — | CN | disclosed |
| US-9962344-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2017-01-26 | — | — | US | disclosed |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2017-01-26 | — | — | US | disclosed |
| US-9463170-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150265555-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2015-09-24 | — | — | US | disclosed |
| US-9050292-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140030332-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | ALDH1A1 764/4885RECQL 3577/4885GLA 3872/4885 |
| US-20150265555-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | ALDH1A1 764/4885RECQL 3577/4885GLA 3872/4885 |
| US-20170020829-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | ALDH1A1 764/4885RECQL 3577/4885GLA 3872/4885 |
| US-20140030332-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | ALDH1A1 764/4885RECQL 3577/4885GLA 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.